Literature DB >> 11732646

Prostate specific antigen: biology, biochemistry and available commercial assays.

A M Ward1, J W Catto, F C Hamdy.   

Abstract

Prostate specific antigen (PSA) is the marker of choice in the management of prostate cancer. However, PSA is not a simple molecule, existing in the serum in five isoforms and a number of molecular configurations and complexes. The elucidation of the biochemistry of PSA has increased the potential use of the marker in the diagnosis of prostate malignancy. This review summarizes the clinical use of PSA in the management of prostate disease and the assays available in the UK. Assay calibration in relation to the World Health Organization 1st International Standard for Prostate Specific Antigen (90:10) has increased conformity between the various commercial assay kits, and the non-equimolar kits have largely been superseded or withdrawn. Special reference is made to evaluations performed on behalf of the Medical Devices Agency of the Department of Health.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732646     DOI: 10.1258/0004563011901055

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  40 in total

1.  Prostate-specific antigen testing. Should we recommend it?

Authors:  John Hickey
Journal:  Can Fam Physician       Date:  2003-03       Impact factor: 3.275

2.  Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.

Authors:  Bhaskara V Chikkaveeraiah; Vigneshwaran Mani; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  Biosens Bioelectron       Date:  2011-05-11       Impact factor: 10.618

3.  High sensitivity carbon nanotube based electrochemiluminescence sensor array.

Authors:  Anita Venkatanarayanan; Karl Crowley; Elena Lestini; Tia E Keyes; James F Rusling; Robert J Forster
Journal:  Biosens Bioelectron       Date:  2011-10-20       Impact factor: 10.618

Review 4.  Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer.

Authors:  James F Rusling; Challa V Kumar; J Silvio Gutkind; Vyomesh Patel
Journal:  Analyst       Date:  2010-07-08       Impact factor: 4.616

Review 5.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

Review 6.  Nanomaterials-based electrochemical immunosensors for proteins.

Authors:  James F Rusling
Journal:  Chem Rec       Date:  2012-01-30       Impact factor: 6.771

7.  Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification.

Authors:  Vigneshwaran Mani; Bhaskara V Chikkaveeraiah; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  ACS Nano       Date:  2009-03-24       Impact factor: 15.881

8.  Nanobiosensors: optofluidic, electrical and mechanical approaches to biomolecular detection at the nanoscale.

Authors:  David Erickson; Sudeep Mandal; Allen H J Yang; Bernardo Cordovez
Journal:  Microfluid Nanofluidics       Date:  2008       Impact factor: 2.529

9.  Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer.

Authors:  Bhaskara V Chikkaveeraiah; Ashwin Bhirde; Ruchika Malhotra; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  Anal Chem       Date:  2009-11-01       Impact factor: 6.986

10.  Subthreshold regime has the optimal sensitivity for nanowire FET biosensors.

Authors:  Xuan P A Gao; Gengfeng Zheng; Charles M Lieber
Journal:  Nano Lett       Date:  2010-02-10       Impact factor: 11.189

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.